Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was submitted on February 3, 2020, covering the month of February 2020. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing discloses the Company's issued share capital as of January 31, 2020. No material changes versus a prior comparable period are detailed in this specific text, as it reports a static snapshot of share capital and treasury holdings.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital figures.
Important Facts for Investors
- Issued Share Capital: As of January 31, 2020, GSK had 5,384,058,616 Ordinary Shares of 25 pence each.
- Treasury Shares: 393,505,950 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,990,552,666.
- Regulatory Use: This voting rights figure serves as the denominator for shareholders calculating notification requirements under FCA rules.